Julia Lansing, APRN
Psychiatric/Mental Health, Adult · Columbus, OHNPI 1518150911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,316, more than ten times the $29 reported in 2021.
Across 159 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$561
- Alkermes, Inc.$457
- AbbVie$418
- Teva Pharmaceuticals USA, Inc.$235
- Axsome Therapeutics, Inc.$226
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$206
- plus $827 from 13 others
What the payments were for
- Food & beverage$2,931100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 23 | $561 |
| Alkermes, Inc. | 31 | $457 |
| AbbVie | 31 | $418 |
| Teva Pharmaceuticals USA, Inc. | 8 | $235 |
| Axsome Therapeutics, Inc. | 7 | $226 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $206 |
| Otsuka America Pharmaceutical, Inc. | 14 | $193 |
| Johnson & Johnson(2 entities) | 10 | $182 |
| E.r. Squibb & Sons, L.L.C. | 7 | $139 |
| Lundbeck LLC | 5 | $76 |
| Almatica Pharma LLC | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Merck | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Braeburn Inc. | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
| Biogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,931 in reported general payments places this provider in the 75th percentile of 42 psychiatric/mental health, adult providers in Ohio.
See all psychiatric/mental health, adult providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 52 | $456,003 |
| IngrezzaValbenazine Tosylate | 27 | $246,291 |
| VraylarCariprazine Hcl | 125 | $179,152 |
| AristadaAripiprazole Lauroxil | 39 | $132,231 |
| Invega SustennaPaliperidone Palmitate | 33 | $121,508 |
| FetzimaLevomilnacipran Hcl | 75 | $44,790 |
| RexultiBrexpiprazole | 17 | $30,220 |
| TrintellixVortioxetine Hydrobromide | 29 | $19,064 |
| Aripiprazole | 56 | $8,547 |
| Methylphenidate ErMethylphenidate Hcl | 18 | $4,902 |
| Paliperidone ErPaliperidone | 26 | $4,568 |
| Olanzapine | 96 | $3,206 |
| Quetiapine Fumarate | 157 | $2,919 |
| Benztropine Mesylate | 173 | $2,713 |
| Oxcarbazepine | 50 | $2,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $235 | $456,00352 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $561 | $246,29127 claims |
| AbbVieVraylar, Fetzima | $418 | $223,942200 claims |
| Alkermes, Inc.Aristada | $457 | $132,23139 claims |
| Johnson & JohnsonInvega Sustenna | $182 | $121,50833 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $193 | $30,22017 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $670115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 42 psychiatric/mental health, adult providers in Ohio.
Other psychiatric/mental health, adult in Columbus
- Sharen RiceColumbus$25
- Latrice WaddellToledo$33K
- David BinghamToledo$12K
- Shirley BuddingDayton$9K
- Joanne VaccaniCanton$8K
- Donna BeaumontAthens$7K
- Dawn GreskoMiddleburg Heights$5K
- Regina EngelCincinnati$5K
- Laura MoyerChesterland$4K
- Grace HerwigWestlake$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.